Gilead's remdesivir set to become Europe's first COVID-19 therapy

Gilead's remdesivir set to become Europe's first COVID-19 therapy

Since then, another phase 3 trial has shown that a five-day treatment course with remdesivir on top of standard care was more effective than standard care alone in moderately-ill patients, although strangely a 10-day course wasn't any better.

Dr. Umanath said that Tamil Nadu was the first State to distribute the drug to every district.

COVID-19 therapy by Covifor will cost less than 30,000 per patient.

AFP reports that at least two major USA studies have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.

He further said that we are working closely with the government and the medical community so that public and private medical institutions across the country can quickly access the "COVIFOR" drug.

The EMA's human medicines committee (CHMP) is backing approval of Gilead's remdesivir - under the brand name Veklury - for the treatment of COVID-19 in patients aged 12 years and over with pneumonia who require supplemental oxygen. The next batch of the drug is to be shipped to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Kochi, Trivandrum and Goa.


The Union Ministry of Health has explained the use of Remdesivir as an investigational treatment antiviral drug in its latest clinical administration for COVID-19 patients.

The EMA endorsement means physicians can prescribe the Gilead drug in Europe once the European Commission, the EU executive, gives its approval, which is now a formality expected over the coming week. The investigational drug of Gilead Ramdesivir had also received an Emergency Use Authorization (EUA) from the US Food and Drug Administration (USFDA) for the treatment of critical COVID-19 hospitalized patients.

Not only in Europe, but the drug is now being used for treating severe COVID-19 cases in the US, India, Japan and South Korea.

In May, domestic pharma firms Hetero, Cipla and Jubilant Life Sciences entered into non-exclusive licensing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of remdesivir.

A prior study in the US, headed by the National Institutes of Health recently discovered it provokes an average recovery period from 15 days to 11 times in hospitalized patients with acute illness.

Related:

Comments

Latest news

Both Sides Must Want An Orderly Brexit, Says Germany's Merkel
It marks the first face-to-face meeting of the two negotiators since March. In a tweet, Frost reported he was coming to Brussels in "fantastic faith".

Newcastle v Manchester City: FA Cup quarter-final
On the win over Toon, Guardiola added: "First we are in the semi-final, it was not easy to attack against defenders so, so deep. It just goes to show, he went away as a youngster and played games and now we welcome him back".

West Indies to wear 'BLM' logo during England series
The three-match Test series between England and West Indies will initiate the resumption of worldwide cricket next month. West Indies coach Phil Simmons said last week that Holder's rivalry with Stokes would be "huge" during this series.

Trafford centre at risk as Intu 'likely' to appoint administrators
Shopping centre owner Intu is on the verge of administration after restructuring talks with lenders fell apart. The owner of the Trafford Centre, Intu, has called in administrators, placing thousands of jobs in doubt.

Australia sees biggest daily rise in COVID-19 cases in 2 months
Over the weekend the government launched a "testing blitz" of ten hotpot suburbs in Melbourne. The Stamford Plaza hotel cluster gained three cases, and the Wollert cluster grew by one.

Other news